AKTS

Aktis Oncology
AKTS

Upgrade to unlock
Buy
Hold
Sell

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
Avg. target
$30
56% upside
High target

3 analyst ratings

positive
0  neutral
0%
negative
Analyst & Firm Rating Price Target Upside
Downside 		Date
HC Wainwright & Co
HC Wainwright & Co
Robert Burns
100% 1-yr AKTS win rate
9 Mar ‘26 2 days ago
Leerink Partners
Leerink Partners
0% 1-yr AKTS win rate
3 Feb ‘26 1 month ago
JP Morgan
JP Morgan
Jessica Fye
0% 1-yr AKTS win rate
3 Feb ‘26 1 month ago